63 related articles for article (PubMed ID: 24071538)
21. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
22. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
[TBL] [Abstract][Full Text] [Related]
23. Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma.
Hong J; Yoon HH; Ahn HK; Sym SJ; Park J; Park PW; Ahn JY; Park S; Cho EK; Shin DB; Lee JH
Acta Haematol; 2013; 130(4):305-11. PubMed ID: 24008775
[TBL] [Abstract][Full Text] [Related]
24. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
25. [Relapse in Hodgkin lymphoma].
Filatova LV; Tarasenkova AA; Gershanovich ML; Semiglazov TIu
Vopr Onkol; 2012; 58(2):265-74. PubMed ID: 22774536
[TBL] [Abstract][Full Text] [Related]
26. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E;
Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
[TBL] [Abstract][Full Text] [Related]
27. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G
Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179
[TBL] [Abstract][Full Text] [Related]
28. [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
Moreno M; Sancho JM; Gardella S; Coll R; García O; Gallardo D; Ribera JM
Med Clin (Barc); 2010 Jan; 134(2):72-5. PubMed ID: 19913261
[TBL] [Abstract][Full Text] [Related]
29. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
30. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.
Lu HJ; Huang YC; Liu CY; Hung MH; Hu MH; Wu CY; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1495-501. PubMed ID: 23712292
[TBL] [Abstract][Full Text] [Related]
31. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
32. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.
Li YL; Pan YY; Jiao Y; Ning J; Fan YG; Zhai ZM
Ann Hematol; 2014 Apr; 93(4):617-26. PubMed ID: 24141331
[TBL] [Abstract][Full Text] [Related]
33. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
[TBL] [Abstract][Full Text] [Related]
34. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
35. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
[TBL] [Abstract][Full Text] [Related]
36. What determines therapeutic choices for elderly patients with DLBCL? Clinical findings of a multicenter study in Portugal.
Alvarez R; Esteves S; Chacim S; Carda J; Mota A; Guerreiro M; Barbosa I; Moita F; Teixeira A; Coutinho J; Príncipe F; Mariz JM; Silva MG
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):370-9. PubMed ID: 24629852
[TBL] [Abstract][Full Text] [Related]
37. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience.
Dixon DO; Neilan B; Jones SE; Lipschitz DA; Miller TP; Grozea PN; Wilson HE
J Clin Oncol; 1986 Mar; 4(3):295-305. PubMed ID: 3512783
[TBL] [Abstract][Full Text] [Related]
38. Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment.
Sanz L; López-Guillermo A; Martínez C; Bosch F; Esteve J; Cobo F; Montoto S; Perales M; Bladé J; Cervantes F; Nomdedeu B; Campo E; Montserrat E
Eur J Haematol; 1998 Jul; 61(1):59-64. PubMed ID: 9688294
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes associated with very late relapses in diffuse large cell lymphoma.
Ko AH; Yuen AR
Leuk Lymphoma; 2002 Sep; 43(9):1789-93. PubMed ID: 12685833
[TBL] [Abstract][Full Text] [Related]
40. Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.
Novak AJ; Asmann YW; Maurer MJ; Wang C; Slager SL; Hodge LS; Manske M; Price-Troska T; Yang ZZ; Zimmermann MT; Nowakowski GS; Ansell SM; Witzig TE; McPhail E; Ketterling R; Feldman AL; Dogan A; Link BK; Habermann TM; Cerhan JR
Blood Cancer J; 2015 Aug; 5(8):e346. PubMed ID: 26314988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]